Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10244037 | 0.90 | CYP1A2 (0.46) | ALDH1A1HPGDNPSR1SMN1; SMN2CYP1A2 | |
| SCHEMBL10244480 | 0.90 | CYP1A2 (0.43) | ACACBALDH1A1HPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL10243525 | 0.86 | ALOX5 (0.54) | ACACBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL10243510 | 0.86 | ALOX5 (0.40) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10243491 | 0.85 | MEN1 (0.45) | ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL10244079 | 0.85 | ALDH1A1 (0.40) | ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL10243433 | 0.85 | MAPT (0.43) | SMN1; SMN2CYP2D6 | |
| SCHEMBL10243623 | 0.85 | HPGD (0.40) | ALDH1A1HPGDNPSR1CYP2D6CYP3A4 | |
| SCHEMBL10243497 | 0.84 | SLC22A1 (0.43) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL10244695 | 0.82 | SMN1; SMN2 (0.41) | ALDH1A1NPSR1SMN1; SMN2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ACACB 4596/4885ALDH1A1 1939/4885HPGD 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.